Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | ADH1A | P07327 | 1/20 | 0.37 |
| ▸ | ADH4 | P08319 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27534430 | 0.84 | SLC6A2 (0.49) | SLC6A2SLC6A4NOS2ADH1CADH1A | |
| SCHEMBL13656777 | 0.83 | ADH1A (0.42) | ADH1CADH1AADH4HTR1DHTR1B | |
| SCHEMBL30859681 | 0.83 | SLC6A2 (0.48) | SLC6A2SLC6A4NOS2ADH1CADH1A | |
| SCHEMBL23988720 | 0.81 | SLC6A2 (0.47) | SLC6A2SLC6A4NOS2ADH1CADH1A | |
| SCHEMBL3798088 | 0.80 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5868706 | 0.79 | SLC6A2 (0.54) | SLC6A2SLC6A4NOS2GNAI3GNAO1 | |
| SCHEMBL13885993 | 0.75 | SLC6A2 (0.51) | SLC6A2SLC6A4NOS2GNAI3GNAO1 | |
| SCHEMBL8781575 | 0.75 | GNAO1 (0.42) | SLC6A2SLC6A4ADH1CADH1AADH4 | |
| SCHEMBL7327926 | 0.74 | GNAO1 (0.44) | ADH1CADH1AADH4GNAI3GNAO1 | |
| SCHEMBL29321537 | 0.73 | SLC6A4 (0.43) | SLC6A2SLC6A4NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305644-B1 | ARALKYL ALCOHOL PIPERIDINE DERIVATIVE AND THE USE AS MEDICAMENT FOR TREATING DEPRESSION | JIANGSU HENGYI PHARMACEUTICAL CO LTD (CN) | 2014-08-27 | — | — | EP | disclosed |
| US-8618133-B2 | Aralkyl alcohol pyridine derivative compounds and the use thereof as medicaments for treating depression | JIANGSU HENGYI PHARMACEUTICAL CO., LTD. (CN) | 2013-12-31 | — | — | US | disclosed |
| US-20110160247-A1 | Aralkyl alcohol piperidine derivative and the use thereof as a medicament for treating depression | JIANGSU GOWORTH INVESTMENT CO. LTD (CN) | 2011-06-30 | — | — | US | disclosed |
| EP-2305644-A1 | ARALKYL ALCOHOL PIPERIDINE DERIVATIVE AND THE USE AS MEDICAMENT FOR TREATING DEPRESSION THEREOF | Jiangsu Goworth Investment Co. Ltd (CN) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160247-A1 | Aralkyl alcohol piperidine derivative and the use thereof as a medicament for treating depression | DRD4, DRD5, DRD3 | SLC6A2 18/4885SLC6A4 4/4885NOS2 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.